This article was originally published in The Gray Sheet
Lake Oswego, Oregon-based firm plans to launch the mycroPhylax and Phylax XM implantable cardioverter defibrillators in the U.S. on Nov. 23 following PMA approval by FDA. The 54 cc, 89 gram mycroPhylax and the 69 cc, 109 gram Phylax XM have the same diagnostics, detection and therapy capabilities. The ICDs will be priced comparably to similar ICDs on the market, Biotronik says
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.